Prevalence and characterization of the IBS subtypes according to the Rome III criteria in patients from a clinical, multicentric study. A report from the Mexican IBS Working Group;Prevalencia y caracterización de los subtipos de SII según los criterios de Roma III, en un estudio clínico, multicéntrico. Reporte del grupo mexicano de estudio para el SII

Revista de Gastroenterologia de Mexico

Volumn 75, Issue 4, 2010, Pages 427-438

  Schmulson, M ^a   Vargas, J A ^b   Lopez Colombo A ^c   Remes Troche, J M ^d   Lopez Alvarenga J C ^e  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^b Nycomed SA de CV   (Mexico)

^c INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^d Universidad de Veracruz   (Mexico)

^e HOSPITAL GENERAL DE MÉXICO   (Mexico)

Author keywords

Dyspepsia; Irritable bowel syndrome (IBS); M xico; Rome III

Indexed keywords

ADULT; ARTICLE; CLASSIFICATION; FEMALE; HUMAN; IRRITABLE COLON; MALE; MEXICO; MULTICENTER STUDY; PREVALENCE;

ADULT; FEMALE; HUMANS; IRRITABLE BOWEL SYNDROME; MALE; MEXICO; PREVALENCE;

EID: 79959914460     PISSN: 03750906     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Kang JY. Systematic review: the influence of geography and ethnicity in irritable bowel syndrome. Aliment Pharmacol Ther 2005 15;21:663-76. (Pubitemid 40468994)
2. Ohman L, Simrén M. Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions. Nat Rev Gastroenterol Hepatol 2010;7:163-73.
3. Schmulson M, Ortiz O, Santiago-Lomeli M, et al. Frequency of functional bowel disorders among healthy volunteers in Mexico City. Dig Dis 2006;24;342-347. (Pubitemid 44114427)
4. López-Colombo A, Bravo-González D, Corona-López A, et al. First community-based study of functional gastrointestinal disorders (FGID) in Mexico using the Modular Rome II Questionnaire. Gastroenterology 2006;130(Suppl 2):A508.
5. Valerio-Ureña J, Vásquez-Fernández F, Jiménez-Pineda A, et al. [Prevalence of irritable bowel syndrome in Veracruz City, Mexico: A community-based survey.]. Rev Gastroenterol Mex. 2010; 75:36-41.
6. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology 2006;130:1480-91.
7. SPSS for Windows, Rel. 15.0. Chicago: SPSS Inc.2006
8. StatSoft, Inc. STATISTICA (data analysis software system), version 9.0. www.statsoft.com.2009.
9. WMA Declaration of Helsinki-Ethical Principles for Medical Research Involving Human Subjects [Internet]. World Medical Association 2008. [Citado el 29 de Sep 2010]. Disponible en:http://www.wma.net/en/30publications/10policies/ b3/index.html
10. Guidelines for Good Pharmacoepidemiology Practices (GPP) [Internet]. 2004. International Society for Pharmacoepidemiology 2004. [Citado el 29 de Sep 2010] Disponible en:http://www.pharmacoepi.org/resources/guidelines-08027.cfm
11. Schmulson M, Adeyemo M, Gutiérrez-Reyes G, et al. Differences in gastrointestinal symptoms according to gender in Rome II positive IBS and dyspepsia in a Latin American population. Am J Gastroenterol 2010;105:925-32.
12. Park DW, Lee OY, Shim SG, et al. The differences in prevalence and sociodemographic characteristics of irritable bowel syndrome according to Rome II and Rome III. J Neurogastroenterol Motil. 2010;16:186-93.
13. Whitehead WE, Drossman DA. Validation of symptom-based diagnostic criteria for irritable bowel syndrome: a critical review. Am J Gastroenterol 2010;105:814-20.
14. Schmulson M, Remes-Troche JM, Vargas JA, et al. Low concordance between physicians clinical classification of IBS subtypes using Rome III criteria, Rome III derived from patients dairies and Rome II based on a structured questionnaire in subjects with active IBS. Gut 2009;58(Suppl 2):P0396.
15. Irvine EJ, Whitehead WE, Chey WD, et al. Design of treatment trials for functional gastrointestinal disorders. En: Drossman DA, Corazziari E, Delvaux M, et al. Editors. Rome III: The Functional Gastrointestinal Disorders. 3rd ed. Allen Press, Inc., Lawrence, KS. 2006.pp.779-834.
16. Hasler WL, Rao SS, Parkman HP, et al. Bristol stool form in slow transit constipation correlates inversely with regional colon contractile activity measured by a wireless motility capsule. Gastroenterology 2010; 138 (Suppl. 1): S-272.
17. Schmulson M, Lopez-Alvarenga JC, Vargas J, et al. Improvement in abdominal pain and stool consistency (Bristol scale) in IBS-Rome III patients alter 4 weeks of treatment with pinaverium bromide 100 mg + simeticone 300 mg BID: a preliminary report of the Mexican IBS working group. Neurogastroenterol Motil 2008;20(Suppl 1):91.
18. Bharucha AE, Zinsmeister AR, Schleck CD, Melton LJ 3rd. Bowel disturbances are the most important risk factors for late onset fecal incontinence: A population-based case-control study in women. Gastroenterology 2010 (in press).
19. Monsbakken KW, Vandvik PO, Farup PG. Perceived food intolerance in subjects with irritable bowel syndrome-etiology, prevalence and consequences. Eur J Clin Nutr 2006;60 667-72. (Pubitemid 43922887)
20. Verdu EF, Armstrong D, Murray JA. Between celiac disease and irritable bowel syndrome: the ";no man's land"; of gluten sensitivity. Am J Gastroenterol 2009;104:1587-94.
21. Lea R, Whorwell PJ. The role of food intolerance in irritable bowel syndrome. Gastroenterol Clin North Am 2005;34:247-55. (Pubitemid 40615954)
22. Sobrino-Cossio S, Morales-Arambula M, Lopez-Alvarenga JC, et al. Do gastroenterologists evaluate patient GERD symptom severity and treatment outcome more accurately than other medical specialists? Usefulness of a combined patient self-assessment Questionnaire (ReQuest®) and a physician symptom Likert scale. Gastroenterology 2009;136(Suppl 1):T1061.